Total Payments
$10,446
2024 Payments
$3,124
Companies
56
Transactions
471
Medicare Patients
19,918
Medicare Billing
$5.6M
Payment Breakdown by Category
Food & Beverage$8,961 (85.8%)
Education$803.62 (7.7%)
Other$681.53 (6.5%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $8,961 | 452 | 85.8% |
| Education | $803.62 | 12 | 7.7% |
| Long term medical supply or device loan | $681.53 | 7 | 6.5% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,135 | 29 | $0 (2024) |
| Merck Sharp & Dohme LLC | $595.32 | 29 | $0 (2024) |
| PFIZER INC. | $574.77 | 33 | $0 (2024) |
| Amgen Inc. | $570.32 | 27 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $537.09 | 17 | $0 (2024) |
| Incyte Corporation | $531.62 | 19 | $0 (2024) |
| Seagen Inc. | $522.34 | 24 | $0 (2023) |
| Astellas Pharma US Inc | $391.00 | 23 | $0 (2024) |
| ABBVIE INC. | $384.66 | 17 | $0 (2024) |
| Daiichi Sankyo Inc. | $349.72 | 15 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $3,124 | 124 | Novartis Pharmaceuticals Corporation ($730.50) |
| 2023 | $3,376 | 161 | Seagen Inc. ($250.57) |
| 2022 | $2,616 | 134 | Merck Sharp & Dohme LLC ($225.88) |
| 2021 | $1,046 | 47 | Seagen Inc. ($146.45) |
| 2019 | $254.94 | 3 | Amgen Inc. ($194.95) |
| 2018 | $28.47 | 2 | Amgen Inc. ($28.47) |
All Payment Transactions
471 individual payment records from CMS Open Payments — Page 1 of 19
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/23/2024 | Geron Corporation | RYTELO (Drug) | Food and Beverage | In-kind items and services | $24.47 | General |
| Category: MYELODYSPLASTIC SYNDROME | ||||||
| 12/13/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $18.29 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 12/05/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $19.42 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 12/02/2024 | Regeneron Healthcare Solutions, Inc. | LIBTAYO (Biological) | Food and Beverage | In-kind items and services | $29.46 | General |
| Category: ONCOLOGY | ||||||
| 11/26/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $19.83 | General |
| Category: Oncology | ||||||
| 11/21/2024 | Stemline Therapeutics Inc. | Orserdu (Drug) | Food and Beverage | In-kind items and services | $21.91 | General |
| Category: Oncology | ||||||
| 11/20/2024 | PFIZER INC. | IBRANCE (Drug), TUKYSA | Food and Beverage | In-kind items and services | $17.82 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Exelixis Inc. | CABOMETYX (Drug) | Food and Beverage | In-kind items and services | $23.51 | General |
| Category: Renal Cell Carcinoma (RCC) Hepatocellular Carcinoma (HCC) Differentiated Thyroid Cancer (DTC) | ||||||
| 11/13/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $19.04 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 11/11/2024 | PFIZER INC. | XTANDI (Drug), ORGOVYX, TALZENNA | Food and Beverage | In-kind items and services | $17.77 | General |
| Category: ONCOLOGY | ||||||
| 11/06/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $25.20 | General |
| 11/05/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $18.00 | General |
| Category: Oncology | ||||||
| 11/04/2024 | Merck Sharp & Dohme LLC | KEYTRUDA (Biological) | Food and Beverage | In-kind items and services | $23.68 | General |
| Category: ONCOLOGY | ||||||
| 10/31/2024 | AstraZeneca Pharmaceuticals LP | CALQUENCE (Drug) | Food and Beverage | In-kind items and services | $17.87 | General |
| Category: Oncology | ||||||
| 10/30/2024 | Astellas Pharma US Inc | Padcev (Drug) | Food and Beverage | In-kind items and services | $12.32 | General |
| Category: Oncology | ||||||
| 10/29/2024 | PFIZER INC. | BOSULIF (Drug), ELREXFIO, ADCETRIS | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: METABOLIC DISEASE;ONCOLOGY | ||||||
| 10/29/2024 | PFIZER INC. | BRAFTOVI (Drug), MEKTOVI | Education | In-kind items and services | $13.04 | General |
| Category: ONCOLOGY | ||||||
| 10/24/2024 | JAZZ PHARMACEUTICALS INC. | ZEPZELCA (Drug) | Food and Beverage | In-kind items and services | $37.73 | General |
| Category: HEMATOLOGY/ONCOLOGY | ||||||
| 10/23/2024 | PFIZER INC. | ELREXFIO (Drug), ADCETRIS | Food and Beverage | In-kind items and services | $8.68 | General |
| Category: ONCOLOGY | ||||||
| 10/22/2024 | GENZYME CORPORATION | SARCLISA (Biological) | Food and Beverage | In-kind items and services | $18.90 | General |
| Category: Oncology | ||||||
| 10/18/2024 | SOBI, INC | SYNAGIS (Drug) | Food and Beverage | In-kind items and services | $18.17 | General |
| Category: IMMUNOLOGY | ||||||
| 10/10/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $21.70 | General |
| Category: Oncology | ||||||
| 10/09/2024 | Gilead Sciences, Inc. | — | Food and Beverage | In-kind items and services | $23.48 | General |
| 10/08/2024 | Genentech USA, Inc. | Columvi (Biological), Lunsumio, Phesgo | Food and Beverage | In-kind items and services | $13.22 | General |
| Category: BioOncology | ||||||
| 10/07/2024 | ABBVIE INC. | VENCLEXTA (Drug) | Food and Beverage | In-kind items and services | $24.64 | General |
| Category: ONCOLOGY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 82 | 8,561 | 196,186 | $7.7M | $2.5M |
| 2022 | 81 | 7,578 | 129,143 | $6.8M | $2.2M |
| 2021 | 58 | 3,779 | 51,746 | $1.8M | $875,153 |
Total Patients
19,918
Total Services
377,075
Medicare Billing
$5.6M
Procedure Codes
221
All Medicare Procedures & Services
221 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| J9271 | Injection, pembrolizumab, 1 mg | Office | 2023 | 55 | 20,800 | $2.9M | $889,278 | 30.5% |
| J9144 | Injection, daratumumab, 10 mg and hyaluronidase-fihj | Office | 2023 | 21 | 12,420 | $931,500 | $465,225 | 49.9% |
| J9299 | Injection, nivolumab, 1 mg | Office | 2023 | 14 | 10,760 | $408,880 | $254,874 | 62.3% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 68 | 10,380 | $348,600 | $187,304 | 53.7% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 828 | 1,427 | $242,636 | $127,883 | 52.7% |
| Q5119 | Injection, rituximab-pvvr, biosimilar, (ruxience), 10 mg | Office | 2023 | 18 | 3,055 | $229,125 | $67,517 | 29.5% |
| 96413 | Administration of chemotherapy into vein, 1 hour or less | Office | 2023 | 252 | 644 | $252,286 | $59,292 | 23.5% |
| J9264 | Injection, paclitaxel protein-bound particles, 1 mg | Office | 2023 | 13 | 5,300 | $106,000 | $52,389 | 49.4% |
| Q5107 | Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg | Office | 2023 | 15 | 2,025 | $388,800 | $45,920 | 11.8% |
| J1439 | Injection, ferric carboxymaltose, 1 mg | Office | 2023 | 43 | 50,250 | $150,750 | $42,875 | 28.4% |
| J0885 | Injection, epoetin alfa, (for non-esrd use), 1000 units | Office | 2023 | 35 | 6,819 | $170,475 | $39,979 | 23.5% |
| Q5111 | Injection, pegfilgrastim-cbqv (udenyca), biosimilar, 0.5 mg | Office | 2023 | 17 | 252 | $148,680 | $27,484 | 18.5% |
| 80053 | Blood test, comprehensive group of blood chemicals | Office | 2023 | 874 | 1,798 | $57,522 | $18,588 | 32.3% |
| 85025 | Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count | Office | 2023 | 1,035 | 2,405 | $64,922 | $18,232 | 28.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 109 | 140 | $30,100 | $17,842 | 59.3% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 29 | 136 | $122,128 | $17,814 | 14.6% |
| 96365 | Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less | Office | 2023 | 199 | 349 | $64,565 | $15,368 | 23.8% |
| 96367 | Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less | Office | 2023 | 163 | 616 | $77,292 | $12,796 | 16.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 102 | 102 | $23,664 | $11,082 | 46.8% |
| G0498 | Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l | Office | 2023 | 20 | 51 | $31,824 | $9,161 | 28.8% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 141 | 154 | $20,020 | $8,950 | 44.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 58 | 58 | $17,400 | $8,882 | 51.0% |
| 82728 | Ferritin (blood protein) level | Office | 2023 | 421 | 604 | $28,992 | $8,060 | 27.8% |
| 96417 | Administration of additional new drug or substance into vein, 1 hour or less | Office | 2023 | 93 | 172 | $33,457 | $7,907 | 23.6% |
| 96401 | Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle | Office | 2023 | 34 | 145 | $23,635 | $7,377 | 31.2% |
About Dr. Marcus Weldon, MD
Dr. Marcus Weldon, MD is a Hematology & Oncology healthcare provider based in Macon, Georgia. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 05/19/2015. The National Provider Identifier (NPI) number assigned to this provider is 1942689286.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Marcus Weldon, MD has received a total of $10,446 in payments from pharmaceutical and medical device companies, with $3,124 received in 2024. These payments were reported across 471 transactions from 56 companies. The most common payment nature is "Food and Beverage" ($8,961).
As a Medicare-enrolled provider, Weldon has provided services to 19,918 Medicare beneficiaries, totaling 377,075 services with total Medicare billing of $5.6M. Data is available for 3 years (2021–2023), covering 221 distinct procedure/service records.
Ad
Practice Information
- Specialty Hematology & Oncology
- Location Macon, GA
- Active Since 05/19/2015
- Last Updated 04/26/2021
- Taxonomy Code 207RH0003X
- Entity Type Individual
- NPI Number 1942689286
Products in Payments
- KISQALI (Drug) $894.88
- KEYTRUDA (Biological) $595.32
- LIBTAYO (Biological) $573.59
- IMBRUVICA (Drug) $356.96
- Xtandi (Drug) $291.17
- VENCLEXTA (Drug) $254.13
- Lenvima (Drug) $250.28
- INJECTAFER (Drug) $208.05
- JAKAFI (Drug) $173.51
- TUKYSA (Drug) $169.13
- SARCLISA (Biological) $137.19
- NINLARO (Drug) $133.43
- MONJUVI (Drug) $133.04
- CALQUENCE (Drug) $132.22
- BOSULIF (Drug) $126.55
- TIVDAK (Biological) $124.31
- Enhertu (Drug) $122.71
- PADCEV (Biological) $121.56
- ZEPZELCA (Drug) $110.96
- BRUKINSA (Drug) $110.62
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Hematology & Oncology Doctors in Macon
Dr. Premila Malhotra, Md, MD
Hematology & Oncology — Payments: $50,530
Hematology & Oncology $50,530
Dr. Arvind Aggarwal, M.d, M.D
Hematology & Oncology — Payments: $32,175
Hematology & Oncology $32,175
Dr. Cheryl Jones, Md, MD
Hematology & Oncology — Payments: $17,239
Hematology & Oncology $17,239
Dr. Franc Wallace, Md, MD
Hematology & Oncology — Payments: $6,208
Hematology & Oncology $6,208
Dr. Farooq Akbar, Md, MD
Hematology & Oncology — Payments: $3,584
Hematology & Oncology $3,584
Dr. Raj Gupta, Md, MD
Hematology & Oncology — Payments: $3,370
Hematology & Oncology $3,370